Marketing-authorisation holder
Janssen Biotech, Inc.
29 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder
29 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 29
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AKEEGA500mg; 100mg base | 500mg; 50mg base · Tablet | Abiraterone, Niraparib | United States | Marketed | 2023 |
| BALVERSA3mg | 4mg | 5mg · Tablet | Erdafitinib | United States | Marketed | 2019 |
| Carvykti0.5 to 1.0x10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg of body weight, with a maximum dose of 1x10^8 CAR-positive viable T cells in one infusion · For Injection | Ciltacabtagene autoleucel | United States | Marketed | 2022 |
| DARZALEX100mg/5ml | 400mg/20ml · Injectable | Daratumumab | United States | Marketed | 2015 |
| DARZALEX FASPRO120mg · Injectable | Daratumumab, Hyaluronidase | United States | Marketed | 2020 |
| ERLEADA240mg | 60mg · Tablet | Apalutamide | United States | Marketed | 2018 |
| ICOTYDE200mg base · Tablet | Icotrokinra | United States | Marketed | 2026 |
| IMAAVY1200mg/6.5ml(185mg/ml) | 300mg/1.62ml(185mg/ml) · Injectable | Nipocalimab | United States | Marketed | 2025 |
| INLEXZO225mg base · System | Gemcitabine | United States | Marketed | 2025 |
| LAZCLUZE240mg base | 80mg base · Tablet | Lazertinib | United States | Marketed | 2024 |
| RYBREVANT350mg/7ml(50mg/ml) · Injectable | Amivantamab | United States | Marketed | 2021 |
| RYBREVANT FASPRO10ml | 14ml · Injection | Amivantamab, Hyaluronidase | United States | Marketed | 2025 |
| RYBREVANT FASPRO1,600mg/20,000 units per 10ml | 2,240mg/28,000 units per 14ml | 2,400mg/30,000 units per 15ml | 3,5200mg/44,000 units per 22ml · Vial | Amivantamab, Hyaluronidase | United States | Marketed | 2026 |
| Simponi50mg/0.5ml · Injection | Golimumab | United States | Marketed | 2009 |
| Simponi100mg/ml · Injection | Golimumab | United States | Marketed | 2013 |
| Simponi100mg/ml · Injection | Golimumab | United States | Marketed | 2013 |
| SIMPONI ARIA50mg/4ml · Injectable | Golimumab | United States | Marketed | 2013 |
| Stelara45mg/0.5ml · Injection | Ustekinumab | United States | Marketed | 2009 |
| Stelara90mg/ml · Injection | Ustekinumab | United States | Marketed | 2009 |
| STELARA130mg/26ml | 45mg/0.5ml | 90mg/1ml · Injectable | Ustekinumab | United States | Marketed | 2009 |
| TALVEY3mg/1.5ml(2mg/ml) | 40mg/ml · Injectable | Talquetamab | United States | Marketed | 2023 |
| TECVAYLI153mg/1.7ml(90mg/ml) | 30mg/3ml(10mg/ml) · Injectable | Teclistamab | United States | Marketed | 2022 |
| Tremfya100mg/ml · Injection | Guselkumab | United States | Marketed | 2019 |
| Tremfya200mg/2ml (100mg/ml) · Injection | Guselkumab | United States | Marketed | 2024 |
| Tremfya200mg/2ml (100mg/ml) · Injection | Guselkumab | United States | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 29 | 29 | 0 | CompaniesAll medicines |
Also in the registers of Brazil
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.